US Patent 12122837 Oncostatin M receptor antigen binding proteins
Patent 12122837 was granted and assigned to Kiniksa Pharmaceuticals on October, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 23 Oct, 2024
Golden AI
Edits made to:
Infobox (+22 properties)
Article (+533 characters)
US Patent 12122837 Oncostatin M receptor antigen binding proteins
Article
Patent abstract
The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Ai Ching Lim0
Chadwick T. King0
Heather A. Arnett0
Nels E. Pederson0
Paul H. Weinreb0
Sabine S. Escobar0
Saravanakumar Narayanan0
Date of Patent
October 22, 2024
0Patent Application Number
174663950
Date Filed
September 3, 2021
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 12122837 Oncostatin M receptor antigen binding proteins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
